LivaNova Highlights CORE-VNS Study Showing VNS Therapy Reduces Seizure Frequency and Healthcare Costs in Drug-Resistant Epilepsy
LivaNova PLC will present eight scientific posters at the American Epilepsy Society Annual Meeting, showcasing real-world evidence from the CORE-VNS study on VNS Therapy for Drug-Resistant Epilepsy. The study indicates reductions in seizure frequency, hospitalizations, emergency visits, and overall healthcare costs. The results will be available to attendees and on the AES website.
LivaNova PLC has announced that it will present eight scientific posters at the upcoming American Epilepsy Society (AES) Annual Meeting, scheduled for December 5-9 in Atlanta. The presentations will showcase real-world evidence from the CORE-VNS study, described as the largest prospective, multinational observational study of VNS Therapy for Drug-Resistant Epilepsy (DRE), as well as new health economics analyses. Among the topics to be presented are healthcare resource use and costs before and after VNS Therapy implantation across different U.S. payer types, with findings indicating reductions in hospitalizations, emergency department visits, and overall costs following VNS Therapy. The results will be available to conference attendees during the meeting, and abstracts and posters will also be accessible on the AES website during and after the congress. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203929955) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
